MedTrace Logo

Barriers and Facilitators of Key Stakeholders to Implement Remote Monitoring Technologies: a Mixed-methods Analysis

NCT05321004 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 18

Last updated 2024-04-10

No results posted yet for this study

Summary

Advancements in digital technologies alongside the global pandemic of COVID-19 have accelerated the adoption of novel healthcare pathways worldwide, with healthcare delivery transitioning beyond the traditional face-to-face model. Telemedicine has gained long over- due exposure during a complicated crisis; as the number of cases continue to grow with second waves predicted, digital modalities have become critical in moderating exposure risk to healthcare staff, reducing community spread, and delivering quality healthcare remotely for exposed or infected individuals.

Remote monitoring solutions are being established internationally to allow individuals to continue living at home rather than in expensive hospital facilities using non-invasive digital technologies (such as wearable sensors) to collect health data, support health provider assessment and clinical decision making.

With the advances in technology miniaturisation, sensors have become increasingly portable, unobtrusive, lightweight, and waterproof, offering an emerging solution to continuous remote monitoring of vital signs. It is predicated that continuous monitoring allows for early recognition of clinical deterioration, and through digital alerting, offers an opportunity for earlier clinical intervention, improving patient care and patient outcomes.

Within the United Kingdom (UK), widespread digital transformations are facilitated by NHS digital, a non-departmental public body created by statute, delivering large health informatics programmes. As such, this study aims to investigate key stakeholder perspectives on an organisational level of implementing remote monitoring solutions, given the pandemic, in the National Health Service (NHS), identifying factors that could affect successful execution and adoption.

Conditions

Interventions

OTHER

Semi-structured interviews will be conducted - there will be no intervention.

The use of semi structured interviews and questionnaires

Sponsors & Collaborators

  • Imperial College London

    lead OTHER

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-03-01
Primary Completion
2023-08-01
Completion
2023-08-01

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05321004 on ClinicalTrials.gov